The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
NCT05839886 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2023-05-06
Summary
This work will evaluate the adverse effects of mitotane treatment in patients treated for ACC with mitotane therapy. All of the individuals were treated at Ruijin Hospital between May 2023 and May 2024.
Conditions
- Adrenocortical Carcinoma
Sponsors & Collaborators
-
Shanghai Jiao Tong University School of Medicine
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-01
- Primary Completion
- 2024-05-01
- Completion
- 2024-12-01
More Related Trials
-
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331 ·Status: RECRUITING ·Phase: PHASE2
-
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
NCT05263986 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient
NCT02338804 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
NCT02940990 ·Status: UNKNOWN ·Phase: PHASE2
-
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
NCT05940896 ·Status: RECRUITING ·Phase: PHASE1
-
Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
NCT04882033 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer
NCT02063893 ·Status: COMPLETED
-
MSLN-targeted CAR-T Cells in Solid Tumors.
NCT05783089 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
NCT04309136 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
NCT05508334 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
NCT04311034 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
NCT04503980 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT03598517 ·Status: UNKNOWN ·Phase: NA
-
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04632108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
NCT04689100 ·Status: UNKNOWN ·Phase: PHASE1
-
PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer
NCT05812326 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
NCT05819684 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
NCT04894825 ·Status: RECRUITING ·Phase: PHASE1
-
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
NCT05089266 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
NCT07229612 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Clinical Study of Metatinib Tromethamine Tablet
NCT02004548 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
NCT07052383 ·Status: RECRUITING ·Phase: PHASE1
-
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
NCT05644509 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Apatinib and MASCT in Patients With Advanced Solid Tumors
NCT02844881 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2